Real-World check: Spesolimab's safety tracked in 52 GPP patients
NCT ID NCT05670821
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times
Summary
This study looked at how safe and effective the drug spesolimab is for people with a severe skin condition called generalized pustular psoriasis (GPP) who have sudden flare-ups. Researchers tracked 52 patients in Japan who were starting spesolimab for the first time, recording any side effects and how their disease changed over time. The goal was to see how the drug works in everyday medical practice, not just in controlled trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.